이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Bicycle Therapeutics 미래 성장
Future 기준 확인 2/6
Bicycle Therapeutics (는) 각각 연간 0.7% 및 50.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 10.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -47.2% 로 예상됩니다.
주요 정보
5.4%
수익 성장률
13.8%
EPS 성장률
Biotechs 수익 성장 | 28.4% |
매출 성장률 | 52.2% |
향후 자기자본 수익률 | -47.2% |
애널리스트 커버리지 | Good |
마지막 업데이트 | 19 Sep 2024 |
최근 미래 성장 업데이트
Recent updates
Bicycle Therapeutics Is Looking Increasingly Attractive
Aug 20Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert
May 24Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why
May 10Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher
May 04Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically
Aug 07News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts
May 08Bicycle Therapeutics EPS misses by $0.05, beats on revenue
May 06수익 및 매출 성장 예측
날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
---|---|---|---|---|---|
12/31/2026 | 63 | -268 | -218 | -159 | 10 |
12/31/2025 | 35 | -236 | -208 | -169 | 12 |
12/31/2024 | 42 | -179 | -139 | -104 | 12 |
6/30/2024 | 40 | -165 | -165 | -164 | N/A |
3/31/2024 | 42 | -168 | -86 | -85 | N/A |
12/31/2023 | 27 | -181 | -64 | -61 | N/A |
9/30/2023 | 25 | -162 | -48 | -44 | N/A |
6/30/2023 | 23 | -140 | -55 | -48 | N/A |
3/31/2023 | 15 | -124 | -122 | -106 | N/A |
12/31/2022 | 14 | -113 | -105 | -86 | N/A |
9/30/2022 | 15 | -101 | -85 | -66 | N/A |
6/30/2022 | 16 | -87 | -54 | -39 | N/A |
3/31/2022 | 14 | -78 | -34 | -27 | N/A |
12/31/2021 | 12 | -67 | -17 | -15 | N/A |
9/30/2021 | 12 | -66 | -22 | -21 | N/A |
6/30/2021 | 11 | -62 | -54 | -53 | N/A |
3/31/2021 | 11 | -56 | -54 | -53 | N/A |
12/31/2020 | 10 | -51 | -19 | -18 | N/A |
9/30/2020 | 12 | -38 | -7 | -6 | N/A |
6/30/2020 | 9 | -37 | -8 | -7 | N/A |
3/31/2020 | 9 | -35 | -4 | -2 | N/A |
12/31/2019 | 14 | -31 | -30 | -29 | N/A |
9/30/2019 | 10 | -33 | -34 | -33 | N/A |
6/30/2019 | 11 | -31 | -28 | -26 | N/A |
3/31/2019 | 11 | -26 | -25 | -24 | N/A |
12/31/2018 | 7 | -22 | -27 | -26 | N/A |
9/30/2018 | 7 | -21 | -20 | -19 | N/A |
12/31/2017 | 2 | -16 | N/A | -1 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: BCYC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: BCYC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: BCYC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: BCYC 의 수익(연간 47.1% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).
고성장 수익: BCYC 의 수익(연간 47.1% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: BCYC (는) 3년 내에 수익성이 없을 것으로 예상됩니다.